{"name":"Kadmon Corporation, LLC","slug":"kadmon-corporation-llc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Infergen and ribavirin","genericName":"Infergen and ribavirin","slug":"infergen-and-ribavirin","indication":"Chronic hepatitis C virus infection","status":"marketed"}]}],"pipeline":[{"name":"Infergen and ribavirin","genericName":"Infergen and ribavirin","slug":"infergen-and-ribavirin","phase":"marketed","mechanism":"Infergen (interferon alfacon-1) is a synthetic interferon that activates innate immune responses to inhibit viral replication, while ribavirin is a nucleoside analog that directly inhibits viral RNA synthesis.","indications":["Chronic hepatitis C virus infection"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxQd1BSdGNva0tpWmhrQ0lfb0F3M3JGX093cTRZczBURnhXVmkwU1VFenJVcndjM1o5X1dVc3YtekpmczhDdHVTSUJ1V3BGdUpvNHdyZElfZjh3V291MEhiYWFqNHp6NDRJZE12ZmRIR1EtajFndjJEUjVXYjJQNENUcnlvZ3FQR21mRHI5Uk9hNFc4U0RZc0Z1bmNB?oc=5","date":"2026-04-07","type":"regulatory","source":"openPR.com","summary":"Chronic Plaque Psoriasis Market Size is to Show Remarkable Growth Trends from 2024 to 2034, estimates DelveInsight - openPR.com","headline":"Chronic Plaque Psoriasis Market Size is to Show Remarkable Growth Trends from 2024 to 2034, estimates DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-gFBVV95cUxPUGZEY2JIYWN3Y2dqeF9RYmtwWlBqa3Nxd1RodUNNOGI3THlfbzBLLVNGaUV1ZXZXMlkzTzluYmFBbzZnckdOSFd0NktuRUFLZkhvOWlwZWJTUkxSaDRfSkUyanFyWndvRnF3aTdJRjhIZWVabkE2NVJaZVNaaEJjeFc0dGIycnktSENVZTJOSGp0aFdxNzRNOEF5a0xOeGRJd01SLVBVTXR2bzNBU2xMYjhqVVMyU1lUOFE5Tzd6ellITkhqcUs3NHVwcEVOTUI5UHFZTTRiU3EtLU1OVkpOanZnVzVBa3lRaDA2X3hYUUtUM3ZqYWFScjFn?oc=5","date":"2026-03-21","type":"trial","source":"Barchart.com","summary":"Recurrent Glioblastoma Clinical Trial Pipeline Shows Potential with Active Contributions from 50+ Key Companies | DelveInsight - Barchart.com","headline":"Recurrent Glioblastoma Clinical Trial Pipeline Shows Potential with Active Contributions from 50+ Key Companies | DelveI","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0AFBVV95cUxPZG5qSUxISzZxRWpZdl9HaXJQXzRrQWM4dXhEMW9mTmVwandjMUhwSTlYVGp0cmZhSHVIYVc5ZENtc1RkdmY5WHZnMGZPajhFTkJyTFcyUEJSSmRGeUJpQ19OdVdJT0g1WGpZd2loNVQ1Q2Rfa244Y2NEYXVUcVdmVlRCREFjUzg0amRvWVNHRjJoUGptc216X2wzRjRJbDYzc2tTSHVmQ3dpYVpIcFJIMnpOdFJ5V0lTamFLUGYxWGp1Y0h0Q3VwTnBtSl9LaG5q?oc=5","date":"2025-08-26","type":"regulatory","source":"BioSpectrum Asia","summary":"Thailand approves Meiji's REZUROCK® for treatment of chronic graft-versus-host disease - BioSpectrum Asia","headline":"Thailand approves Meiji's REZUROCK® for treatment of chronic graft-versus-host disease","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMitwJBVV95cUxQWHNuMmYyU0dYeFRna1RXMU02ck5fSklQZllyVFpBREZXNTRGOHJDejZGcGx4RzBFQzhXeDlpalAyOE8xWTlyTmZVUDAyZkhPV2xoNTZlRkRwOHBhUk14VnBOcEhQN3ZOaDdkb3lJZEdsaVRjWk9mS0tDRGU0VDRyQ0JYX0FlSHh5RjFaeWpab0hiNkwwZVk5NHhPNndOTGFPcWRpRjZJUllGVklqNEtZWnZGNVJidWJQbHA5SzYxRmJPT3JSdDZhZ0hKRjJFRmNUek9WUnU4R3NSOWt4bDhWTUI4RzB5WWYxXzRHa3RhbDU2a3UxY3RXYlBLbHNlLXU3bnNwazZEbS15MXFSdEVDaE5ZU0pfb0N2YXB0eWRTN0dQb3lzTTdaek5EMEFGaDVheng3ZFJkYw?oc=5","date":"2023-05-25","type":"trial","source":"PR Newswire","summary":"Idiopathic Pulmonary Fibrosis Clinical Trial Pipeline Appears Robust With 80+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - PR Newswire","headline":"Idiopathic Pulmonary Fibrosis Clinical Trial Pipeline Appears Robust With 80+ Key Pharma Companies Actively Working in t","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxQLUVvNTJDYk1JNHRHelFGdm00T0lfN1BaaWRPbE9SaFVpQXFLLUxBTXM0RTZUR05HYTRvWUVzelRRaVNiNXFSRVNVUi1GTHp1c2xyQWk0RktYLUphQlNkZ05MN1EydUw1c2RmekluSTd2YWN0ZWE1R3FqeVVXcXJEM0U4ZC1iYWxYOF9hUmJYalBpdVBmNGlqaGUyMVlmdw?oc=5","date":"2022-04-06","type":"deal","source":"Fierce Pharma","summary":"Sanofi cuts 2 dozen Kadmon staffers after $1.9B buyout - Fierce Pharma","headline":"Sanofi cuts 2 dozen Kadmon staffers after $1.9B buyout","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxNUXNRRUQxSlFiNnUtMC05M29LamxWTkktVzJDM2xITEhWVXZodndLaVNjUnpMY0k0NkF4UDZ6QVlvd1Q1NXp4VXNPMUxCZEN6YXdhczRQQWdxT2c3ZmV0SGNwY3RJVFBxXzZZYjg0WGlyaHNNTlR4MGVkbVZZVWh1VE5yUFlmUzhsYUNWeHprd25SeTBaMzJlRWtVSGFIRUFzN3RMM2N2S1JfMTV6R2QxWklSNXY?oc=5","date":"2021-09-22","type":"deal","source":"Fierce Pharma","summary":"Play-by-play: How Sanofi jacked up its offer twice to seal the $1.9B deal for Kadmon - Fierce Pharma","headline":"Play-by-play: How Sanofi jacked up its offer twice to seal the $1.9B deal for Kadmon","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4gFBVV95cUxPZEJOMDZuUnFXcFFqTmlWU0YwbHViZDJZU2p1TTljbmZEUVl4SDBGNWFxM3RVY2gxbVFRU3dMRmI2Q2RMcEk0ZGdlSkRDMG9WbEMtSnZPdWRYVklhWXlUTW1vRmZrOThLZm40WXFaS1JDODU2TXlQdk43Sy1pb2dLeUdwd3l4UmpGU2hYX2dJTldjS1VtRW1VTEF0NGprOUNuUUlDeUY4bEZhRVdDZXRLTlVZYzF5VGctSVhFZGtDbjdNZ0ZvMmVWRWtLSTEzZkVJeWt5QU12eHdxNy1MdDFzLUd3?oc=5","date":"2021-09-08","type":"deal","source":"GlobeNewswire","summary":"Sanofi to acquire Kadmon to further strengthen growth of transplant business - GlobeNewswire","headline":"Sanofi to acquire Kadmon to further strengthen growth of transplant business","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxOQjVjdGlZdUNhN0IxUkNnWGFhcG50UEZ5ZURfekFRcnJEanZTbGEtaU00ODVtVGxUTzNaWE12V3g2QkE2V001QTZ5OVF4YkRsRHpjcHJERGdpN0JxVkJvWHlNVW1GaWEydHBXRThXaGc4V2g1ZzNlLXJVdkFMRTBULW1EbFBiY1RjcUlyc1ZpTmhLX2QyQWRFbmVVX3k4dGdYR1lCMjR3?oc=5","date":"2019-04-15","type":"pipeline","source":"Dermatology Times","summary":"Psoriasis research advances treatments for inflammatory skin diseases - Dermatology Times","headline":"Psoriasis research advances treatments for inflammatory skin diseases","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxOX3g0MUxtQnNOcmNDbXFhaGc0T2NiQzdLNE1meXkyb213SU9aMGxyM2FwX3VDMTkxZXp2ejJTQXJkaVVYcXl0SHZ5WG5FWVZ0UzdWSXpDdjlHbWxScVNIRU9GX3VyOGF1V09hMVJULTFEVk5IQXRkeXpvRG1zR0pZRGxyRW1MMmdsLTd4LUN5cXlCTVFJSVdXTjdtbExmM3dxYkVIWUxCbzdQdmJvd2c?oc=5","date":"2015-06-29","type":"deal","source":"Bloomberg.com","summary":"Waksal Sued by Barred Ex-John Thomas Head Belesis Over Deal - Bloomberg.com","headline":"Waksal Sued by Barred Ex-John Thomas Head Belesis Over Deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxPaDF2aVZsaXJ4SGYzYklzNmRkcGcxeHlFV2RGX2M3bjNiU0p4QTBYamdPc1Etb1BsSWpSOVdtZXNZT0gwSGdmM1lCQ3J2U0l0dDlmZDNzTUNhUWNxN1h4VFdRQlB3ZV9Dd0kyM2thYXlJYXlSZFoxSWU4d1VCM0lXMVU5cEwzNVdZ?oc=5","date":"2010-10-25","type":"deal","source":"Contract Pharma","summary":"Kadmon Acquires Three Rivers Pharma - Contract Pharma","headline":"Kadmon Acquires Three Rivers Pharma","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}